title: Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma.
abstract: OBJECTIVE
  Advanced biliary carcinoma have poor prognosis and chemotherapy has been shown to have little impact. The aim of the present study is to clarify the effectiveness of GEM combined with CDDP and 5FU (GFP) therapy for unresectable biliary carcinoma.
  
  
  METHODS
  Fourteen patients with biliary carcinoma (4 patients; gallbladder cancer, 10 patients; biliary tract) who had no prior chemotherapy were enrolled. A triple combination of agents was administered with a 4-week cycle GFP chemotherapy consisting of GEM at 1000 mg/m2 on days 1 and of 5-FU at 250 mg/m2 and CDDP at 3mg/m2 on days 1 to 5.
  
  
  RESULTS
  No patient achieved CR, while five patients achieved PR as assessed by RECIST. The overall response rate from the intent-to-treat analysis was 21.4%. Stable disease was observed in 9 (64.3%) patients. Clinical benefit rate was observed in 14 (85.7%) patients. According to the tumor site, overall response rate was 20.0% in biliary tract carcinoma, on the other hand, 25.0% in gallbladder carcinoma.
  
  
  CONCLUSIONS
  The significant antitumor activity of GFP chemotherapy has been seen in patients with advanced biliary carcinoma. However, further evaluation in large numbers of patients is needed to determine the difference in chemosensitivity according to the tumor site.
authors: Department of Digestive Surgery, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima, 770-8503, Japan.
authors: Yuji
authors: Y
authors: Morine
authors: Mitsuo
authors: M
authors: Shimada
authors: Toru
authors: T
authors: Ikegami
authors: Satoru
authors: S
authors: Imura
authors: Hirohumi
authors: H
authors: Kanemura
authors: Yusuke
authors: Y
authors: Arakawa
authors: Jun
authors: J
authors: Hanaoka
authors: Mami
authors: M
authors: Kanamoto
authors: Akira
authors: A
authors: Nii
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001650:Bile Duct Neoplasms / Q000188:drug therapy*; D016009:Chi-Square Distribution; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D005706:Gallbladder Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018709:Statistics, Nonparametric; D015996:Survival Rate; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D002945:Cisplatin; D005472:Fluorouracil; D000093542:Gemcitabine